Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Swiss spec pharma ObsEva completes $90mm IPO on Nasdaq

Executive Summary

Three months after an October 2016 announcement of its intent to go public in the US, Swiss women’s health company ObsEva SA (small-molecule therapeutics for serious conditions in reproductive health and pregnancy) netted $90mm in an IPO on Nasdaq of 6.45mm shares at $15, the mid-point of its anticipated range.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies